Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) and Entera Bio (NASDAQ:ENTX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares Lexeo […]
Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have been assigned an average recommendation of “Buy” from the six research firms that are covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued ratings on the […]
Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have received an average recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have covered the stock in the last […]
Lexeo Therapeutics’ (NASDAQ:LXEO – Get Free Report) quiet period will expire on Wednesday, December 13th. Lexeo Therapeutics had issued 9,090,910 shares in its public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. During Lexeo Therapeutics’ quiet period, insiders and underwriters involved in the […]
Leerink Partnrs restated their outperform rating on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a research report report published on Tuesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q4 2023 earnings at ($0.73) EPS and FY2024 earnings at ($2.13) EPS. Several other equities research analysts also recently weighed in […]